S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
A gold storm is coming… (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
A gold storm is coming… (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
A gold storm is coming… (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
A gold storm is coming… (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
NASDAQ:BGNE

BeiGene - BGNE Stock Forecast, Price & News

$256.90
+1.85 (+0.73%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$251.94
$257.72
50-Day Range
$179.29
$274.50
52-Week Range
$118.18
$280.62
Volume
346,549 shs
Average Volume
265,132 shs
Market Capitalization
$26.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$286.43

BeiGene MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
11.5% Upside
$286.43 Price Target
Short Interest
Healthy
1.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of BeiGene in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$9.41 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($17.64) to ($12.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

734th out of 1,028 stocks

Pharmaceutical Preparations Industry

362nd out of 501 stocks

BGNE stock logo

About BeiGene (NASDAQ:BGNE) Stock

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Update
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Analysts Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $286.43
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
What 5 Analyst Ratings Have To Say About BeiGene
Why Shares of BeiGene Were Up Wednesday
SVB Securities Keeps Their Buy Rating on BeiGene (BGNE)
BeiGene to Present at Upcoming Investor Conferences
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Company Calendar

Last Earnings
11/09/2022
Today
2/05/2023
Next Earnings (Estimated)
2/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
8,200
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$286.43
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$213.00
Forecasted Upside/Downside
+11.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-1,413,350,000.00
Net Margins
-171.94%
Pretax Margin
-169.38%

Debt

Sales & Book Value

Annual Sales
$1.18 billion
Book Value
$60.95 per share

Miscellaneous

Free Float
96,159,000
Market Cap
$26.71 billion
Optionable
Optionable
Beta
0.72

Social Links


Key Executives

  • John V. OylerJohn V. Oyler
    Chairman & Chief Executive Officer
  • Xiao Bin WuXiao Bin Wu
    President & Chief Operating Officer
  • Julia Wang
    Chief Financial & Accounting Officer
  • Christiane Langer
    Senior Vice President-Global Medical Affairs
  • Mark Lanasa
    Chief Medical Officer













BGNE Stock - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BGNE shares.
View BGNE analyst ratings
or view top-rated stocks.

What is BeiGene's stock price forecast for 2023?

6 brokers have issued 12-month target prices for BeiGene's stock. Their BGNE share price forecasts range from $213.00 to $350.00. On average, they expect the company's share price to reach $286.43 in the next twelve months. This suggests a possible upside of 11.5% from the stock's current price.
View analysts price targets for BGNE
or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2023?

BeiGene's stock was trading at $219.94 at the beginning of the year. Since then, BGNE stock has increased by 16.8% and is now trading at $256.90.
View the best growth stocks for 2023 here
.

Are investors shorting BeiGene?

BeiGene saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 1,920,000 shares, a decline of 6.3% from the December 31st total of 2,050,000 shares. Based on an average trading volume of 268,800 shares, the short-interest ratio is currently 7.1 days.
View BeiGene's Short Interest
.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our BGNE earnings forecast
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($5.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.02) by $1.37. The business earned $387.63 million during the quarter, compared to analysts' expectations of $360.25 million. BeiGene had a negative trailing twelve-month return on equity of 38.92% and a negative net margin of 171.94%.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.28%), M&G Investment Management Ltd. (0.12%), DekaBank Deutsche Girozentrale (0.03%), SG Americas Securities LLC (0.02%), Sumitomo Mitsui Trust Holdings Inc. (0.02%) and State of New Jersey Common Pension Fund D (0.01%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends
.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $256.90.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $26.71 billion and generates $1.25 billion in revenue each year. The company earns $-1,413,350,000.00 in net income (profit) each year or ($21.35) on an earnings per share basis.

How many employees does BeiGene have?

The company employs 8,200 workers across the globe.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at (345) 949-4123 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 2/5/2023 by MarketBeat.com Staff